Puma Biotechnology (PBYI) Consolidated Net Income (2010 - 2026)

Puma Biotechnology has reported Consolidated Net Income for 17 years, with the latest figure at -$3.8 million in Q1 2026.

• For the quarter ending Q1 2026, Consolidated Net Income fell 226.19% year-over-year to -$3.8 million; the trailing twelve-month figure through Mar 2026 stood at $27.6 million (up 290.96% YoY), and the FY2025 full-year result was $34.4 million, up 4858.45% from the prior year.
• Consolidated Net Income for Q1 2026 stood at -$3.8 million, down from $16.7 million in the prior quarter.
• The five-year high for Consolidated Net Income was $20.3 million in Q3 2024, with the low at -$11.7 million in Q4 2024.
• Historically, Consolidated Net Income has averaged $1.7 million across 5 years, with a median of $1.4 million in 2023.
• Annual changes were most pronounced in 2023 — Consolidated Net Income surged 1710.0% — and 2024, when it slumped 443.68%.
• Puma Biotechnology's Consolidated Net Income stood at -$5.5 million in 2022, then tumbled by 88.72% to -$10.4 million in 2023, then dropped by 12.39% to -$11.7 million in 2024, then surged by 242.65% to $16.7 million in 2025, then tumbled by 122.5% to -$3.8 million in 2026.
• The last three Consolidated Net Income figures came in at -$3.8 million (Q1 2026), $16.7 million (Q4 2025), and $8.8 million (Q3 2025), per Business Quant data.